Abstract: The use of O-esters of L-carnitine with aromatic acids, such as salicylic, acetylsalicylic, nicotinic and trimethoxybenzoic acid is disclosed for producing pharmaceutical compositions suitable to be topically applied for treating dermatoses, such as ichthyosis and psoriasis.

Abstract: L-carnitine acid azelate and its use for producing cosmetic and pharmaceutical compositions suitable to be topically applied for the treatment of dermatoses, are disclosed.

Abstract: Dermatosis is treated by a method comprising topically applying an effective amount of an ester of L-carnitine or an acyl L-carnitine with a hydroxy carboxylic acid selected from the group consisting of .alpha.-hydroxybutyric acid, .alpha.-hydroxyisocaproic acid, .alpha.-hydroxyisovaleric acid, malic acid and tartronic acid, to a patient in need thereof.

Abstract: L-carnitine trichloroacetate and its use for producing cosmetic and pharmaceutical compositions suitable to be topically applied for the treatment of dermatoses, are disclosed.

Abstract: L-carnitine glycolate, a novel stable and non-hygroscopic salt of L-carnitine and the use thereof for preparing orally administrable, particularly solid compositions in the form of pills, tablets, troches, capsules, powders and the like, are disclosed.

Abstract: The L-carnitine ester with gamma-hydroxybutyric acid and its pharmacologically acceptable salts of formula (I) ##STR1## wherein X.sup.- is the anion of a pharmacologically acceptable salt, e.g. chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, acid fumarate, lactate, acid maleate, acid oxalate, acid sulfate and glucosephosphate are active in inhibiting neuronal degeneration (as it occurs in Alzheimer's senile dementia and Parkinson's disease) and in the treatment of coma.

Abstract: The esters of acyl L-carnitines with gamma-hydroxybutyric acid in the form of pharmacologically acceptable salts of formula (I) ##STR1## wherein X.sup.- is the anion of a pharmacologically acceptable salt, e.g. chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, acid fumarate, lactate, acid maleate, acid oxalate, acid sulfate and glucosephosphate or in the form of inner salts of formula (I') ##STR2## wherein R is a straight or branched acyl group having from 2 to 5 carbon atoms, such as e.g. acetyl, propionyl, n-butyryl, isobutyryl and isovaleryl, are active in inhibiting neuronal degeneration (as it occurs in Alzheimer's senile dementia and Parkinson's disease) and in the treatment of coma.

Abstract: The esters of acyl L-carnitines with gamma-hydroxybutyric acid in the form of pharmacologically acceptable salts of formula (I) ##STR1## wherein X.sup.- is the anion of a pharmacologically acceptable salt, e.g. chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, acid fumarate, lactate, acid maleate, acid oxalate, acid sulfate and glucosephosphate or in the form of inner salts of formula (I') ##STR2## wherein R is a straight or branched acyl group having from 2 to 5 carbon atoms, such as e.g. acetyl, propionyl, n,butyryl, isobutyryl and isovaleryl, are active in inhibiting neuronal degeneration (as it occurs in Alzheimer's senile dementia and Parkinson's disease) and in the treatment of coma.

Abstract: The use of O-esters of L-carnitine with saturated bicarboxylic acids (e.g. azelaic, sebacic, suberic and pimelic acid) or unsaturated monocarboxylic acids (e.g. linoleic, linolenic, oleic and orachidonic acid) is disclosed for producing pharmaceutical compositions suitable to be topically applied for treating dermatoses, such as ichthyosis and psoriasis.

Abstract: The use is described of acetyl D-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of glaucoma. The medicament may be administered orally or parenterally or be applied as a collyrium containing approximately 1-10% w/v of acetyl D-carnitine.

Abstract: A novel therapeutical use of L-carnitine, acyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed for the treatment of non-insulin-dependent patients with a view to enhancing their peripheral glucose utilization.

Abstract: Ester of L-carnitine and alkanoyl L-carnitines with glycolic acid and esters thereof are disclosed, which are formulated into topically applicable pharmaceutical compositions for the treatment of dermatoses.

Abstract: Amides of alkanoyl L-carnitines of general formula (1). ##STR1## wherein R is a straight or branched alkanoyl group having from 2 to 8 carbon atoms selected from acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, hexanoyl, 1-methylbutyryl, t-butylacetyl, 2-ethylbutyryl, 3-methylvaleryl, 4-methylvaleryl, 2-ethylhexanoyl and 2-propylpentanoyl;R' is the monovalent residue of a naturally occurring aminoacid selected from: ##STR2## X.sup.- is the anion of a pharmacologically acceptable acid are active in regenerating the nervous tissue, inhibiting neuronal degeneration, enhancing the processes of learning and memory and for the treatment of coma.Orally or parenterally administrable compositions in unit dosage form comprise between about 50 and about 500 mg of an amide of formula (1).

Abstract: The use is disclosed of compounds of general formula ##STR1## wherein: Y is hydrogen or methyl andR is an unsubstituted or substituted alkyl group selected from methyl, ethyl and isopropyl,and the pharmacologically acceptable salts thereof, for treating myopathies, neuronal degeneration and some pathologies affecting the liver, skeletal muscles and myocardium.The compounds can be administered orally or parenterally.

Abstract: The use is described of acetyl L-carnitine and some of its pharmacologically acceptable salts in the therapeutic treatment of coma. 2000-4000 mg/day of acetyl L-carnitine or an equivalent quantity of one of its pharmacologically acceptable salts is administered, preferably by the parenteral route.

Abstract: A new crystalline form of magnesium valproate obtained by reacting valproic acid with magnesium alkoxides in alcoholic solution is described.The new crystalline form is endowed with enhanced bioavailability and may be used in a particularly pure form to prepare pharmaceutical compositions which are useful for treating Central Nervous System pathologies.

Abstract: 3-methylthiopropionyl L-carnitine and its pharmacologically acceptable salts are active on the cardiovascular system, particularly in the treatment of myocardial anoxia, cardiac ischaemia, arrhythmias and congestive heart failure.

Abstract: The use is described of acetyl D-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of glaucoma. The medicament may be administered orally or parenterally or be applied as a collyrium containing approximately 1-10% w/v of acetyl D-carnitine.

Abstract: The use is disclosed of compounds of general formula ##STR1## wherein: Y is methyl, andR is an unsubstituted or substituted alkyl group selected from methyl, or ethyl,and the pharmacologically acceptable salts thereof, for treating peripheral neuropathies.The compounds can be administered orally or parenterally.

Abstract: The use is described of acetyl L-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of cataract. The medicament may be administered orally or parenterally or be applied as a collyrium containing approximately 10%-15% w/v of acetyl L-carnitine.